AriBio’s AR1001 Meets Primary Goal Only in 604 Monotherapy Patients in Phase 3 Alzheimer’s Disease Trial

Written by

in

In the Phase 3 POLARIS-AD trial involving 1,535 patients with early Alzheimer’s disease, AR1001 did not meet the primary endpoint in the overall population, but achieved the prespecified goal in the 604-patient monotherapy group not using other Alzheimer’s disease medications.

Source:Tech Times · Read original

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *